Status:
COMPLETED
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
Lead Sponsor:
MacroGenics
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if margetuximab is effective in the treatment of certain patients with relapsed or refractory advanced breast cancer.
Detailed Description
In the pivotal study that established that Herceptin® was highly effective when added to standard chemotherapy in the front-line treatment of women with HER2 positive metastatic breast cancer, benefit...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed invasive carcinoma of the breast
- Treatment with at least two prior systemic therapies for advanced (unresectable locoregional or metastatic) disease
- Evidence of HER2 oncoprotein expression at the 2+ level by central laboratory. Patients whose tumors exhibit 2+ staining by IHC are eligible for the study.
- Patients whose tumors score 1+ by conventional IHC, are non-amplified by FISH testing, and whose tumors score \> or = 10.5 by HERmark® testing, are eligible for the study.
- Evidence of lack of HER2 oncogene amplification as determined by FISH testing by central laboratory
- Performance Status of 0 or 1
- Life expectancy at least 6 months
- Measurable disease (by RECIST 1.1)
- Acceptable laboratory parameters and organ reserve
- Baseline left ventricular ejection fraction \> or = 50%
- Anti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to \</= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.
- Patients who are estrogen receptor+ and/or progesterone receptor+ and who are receiving anti-hormone therapy for at least three months may continue to receive such therapy during the course of the trial
- Eighteen (18) years of age or older
Exclusion
- Major surgery or trauma within 4 weeks
- Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation
- Second primary malignancy that has not been in remission for more than 3 years
- History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 days
- History within 3 months of deep vein thrombosis, pulmonary embolism, or stroke
- Symptomatic or untreated central nervous system (CNS) metastatic disease. Patients with previously treated CNS metastatic disease which has been stable for at least 56 days are eligible
- Requirement, at time of study entry, for concurrent steroids \> 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray, or ophthalmic solution
- Serious medical condition that would impair the ability to receive or tolerate margetuximab; dementia or altered mental status that would preclude provision of informed consent
- Uncontrolled hypertension, heart disease including history of congestive heart failure, history of myocardial infarction, angina pectoris requiring medication, clinically significant valvular heart disease, high risk arrhythmias, or disease corresponding to New York Heart Association class III or IV.
- Significant pulmonary compromise
- Have previously been exposed to MGAH22 in this or any other trial
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2017
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01828021
Start Date
March 1 2013
End Date
April 14 2017
Last Update
March 13 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94115
2
Stanford University
Stanford, California, United States, 94305
3
Florida Cancer Research Institute
Plantation, Florida, United States, 33324
4
Indiana University
Indianapolis, Indiana, United States, 46202